Gosset Ownership
Private
Employees
~5
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Zhongze Therapeutics General Information
The company’s lead candidate SIPI6398 has completed first-in-human studies showing safety and tolerability with promising pharmacokinetics. It targets multiple dopamine and serotonin receptors to address both positive/negative symptoms as well as cognitive impairment in schizophrenia. A phase II combo drug for substance use disorder and a gut-brain axis peptide are also advancing through early clinical development. The company integrates target-based and phenotypic screening with precision neurology to accelerate CNS therapy development.
Contact Information
Primary Industry
Biotech
Corporate Office
Shanghai,
China
China
Drug Pipeline
ZZ6398
Phase 1Key Partnerships
Zhongze Therapeutics Funding
No funding data available
To view Zhongze Therapeutics's complete valuation and funding history, request access »